No Data
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 10% Over the Past Week
Key Insights Given the large stake in the stock by institutions, Y-mAbs Therapeutics' stock price might be vulnerable to their trading decisions A total of 9 investors have a majority stake in the
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Express News | Y-mAbs Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $23
JonesTrading Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
JonesTrading analyst Justin Walsh initiates coverage on $Y-mAbs Therapeutics(YMAB.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate
MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects MSC Industrial Direct Co., Inc. (NYSE:MSM) to re
Y-Mabs Therapeutics Welcomes New CFO Amid Strategic Shift